Results 161 to 170 of about 214,982 (356)

Interconnected pathways and emerging therapies in chronic kidney disease and heart failure: A comprehensive review

open access: yesESC Heart Failure, EarlyView.
Abstract Chronic kidney disease (CKD) and chronic heart failure (HF) frequently coexist and, when comorbid, are associated with poorer outcomes. These two diseases have common risk factors, such as diabetes, obesity and hypertension, and common pathophysiological connected mechanisms, including inflammation, endothelial dysfunction, neurohormonal ...
Johann Bauersachs   +2 more
wiley   +1 more source

Angiotensin receptor‐neprilysin inhibitors in concurrent heart failure with reduced ejection fraction and kidney failure

open access: yesESC Heart Failure, EarlyView.
Abstract Aims Angiotensin receptor‐neprilysin inhibitor (ARNI) therapy has demonstrated improved outcomes in heart failure with reduced ejection fraction (HFrEF). However, its benefits in patients with concomitant kidney failure undergoing replacement therapy remain uncertain. Methods and results Using the National Health Insurance Service database, we
Mi‐Hyang Jung   +8 more
wiley   +1 more source

Clinical endpoints in pragmatic heart failure trials: From data collection to clinical endpoint classification

open access: yesESC Heart Failure, EarlyView.
Abstract Clinical endpoint classification (CEC)—that is, evaluation of clinical events using pre‐defined criteria—is commonly conducted in clinical trial operations to ensure systematic and consistent assessment of endpoints needed to assess the intervention's safety and efficacy.
Veraprapas Kittipibul   +13 more
wiley   +1 more source

The immunological reactivity and biological activity of synthetic glucagon [PDF]

open access: bronze, 1969
K. F. Weinges   +4 more
openalex   +1 more source

Registries on transcatheter edge‐to‐edge repair in heart failure: Current evidence and future perspectives

open access: yesEuropean Journal of Heart Failure, EarlyView.
Clinical evidence in transcatheter edge‐to‐edge valve repair. EF, ejection fraction; eGFR, estimated glomerular filtration rate; EROA, effective regurgitant orifice area; GDMT, guideline‐directed medical therapy; HF, heart failure; HHF, hospitalization for heart failure; LVEDV, left ventricular end‐diastolic volume; MR, mitral regurgitation; MVARC ...
Gianluigi Savarese   +13 more
wiley   +1 more source

The interaction between atrial fibrillation and mitral regurgitation: Insights from the CABANA randomized clinical trial

open access: yesEuropean Journal of Heart Failure, EarlyView.
Effects of baseline mitral regurgitation in the CABANA trial: randomization to catheter ablation versus drug therapy in patients with atrial fibrillation. AF, atrial fibrillation; CCS, Canadian Cardiovascular Society; MR, mitral regurgitation; NYHA, New York Heart Association; OR, odds ratio.
Sebastiaan Dhont   +8 more
wiley   +1 more source

Why Glucagon Matters for Hypoglycemia and Physical Activity in Individuals With Type 1 Diabetes

open access: yesFrontiers in Clinical Diabetes and Healthcare, 2022
Sheri R. Colberg
doaj   +1 more source

Home - About - Disclaimer - Privacy